Thursday Jul 24
Mead Johnson Nutrition Co PT Raised to $92.00
The firm currently has a "market perform" rating on the stock. BMO Capital Markets' target price would indicate a potential downside of 3.24% from the stock's previous close.
Mead Johnson Nutrition's (MJN) CEO Kasper Jakobsen on Q2 2014 Results - Earnings Call Transcript
Good day, ladies and gentlemen, and welcome to the Mead Johnson Nutrition Second Quarter and First Half 2014 Earnings Conference Call.
Press release distribution, EDGAR filing, XBRL, regulatory filings
Coca-Cola Internation... )--Mad Catz Interactive, Inc. announced today the shipping of the first products in its range of licensed audio headsets for Xbox One under ... )--FUND db x-trackers S&P 500 Shariah UCITS ETF DEALING DATE 21-Jul-14 NAV PER SHARE USD19.7571 NUMBER OF SHARES IN ISSUE 510,000 CODE )--Research and Markets has announced the ... (more)
Mead Johnson Nutrition CO Given Consensus Rating of "Buy" by Analysts
Mead Johnson Nutrition CO has earned a consensus rating of "Buy" from the twelve analysts that are covering the stock, StockRatingsNetwork.com reports .
Insider Selling: Mead Johnson Nutrition CO Director Unloads 10,000 Shares of Stock
Mead Johnson Nutrition CO Director Stephen W. Golsby sold 10,000 shares of Mead Johnson Nutrition CO stock in a transaction dated Tuesday, July 15th.
Mead Johnson Nutrition CO Price Target Increased to $97.00 by Analysts at JPMorgan Chase & Co.
JPMorgan Chase & Co.' s price objective would suggest a potential upside of 4.45% from the company's current price.
Expert Witnesses Not Required to Rule Out All Possible Causes in Product Liability Actions
On June 6, 2014, the 8th Circuit Court of Appeals reversed a district court decision excluding three experts, who were critical to the plaintiff to show causation, on the basis that they did not reliably rule out alternative causes of injury.